Clinical trials: Stem Cell Mobilization
Non-Hodgkin's Lymphoma, Hodgkin's Disease
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
The purpose of this program is to provide expanded access to plerixafor for patients with NHL, HD, or MM who are to receive treatment with an autologous peripheral stem cell transplant.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
- Trial name
- EAP (NCT00720603)
- Testing
- Plerixafor
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma
Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
Eltrombopag may improve the cell collection available for Autologous Stem Cell Transplant(ASCT). The overall goal is to determine if adding Eltrombopag to the standard ASCT will increase the number of blood cells collected and…
- Trial name
- NCT01286675
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies.
- Trial name
- NCT01146834
- Testing
- bortezomib (Velcade), cyclophosphamide, G-CSF
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Weill Medical College of Cornell University
Peripheral Arterial Disease
Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease
Peripheral arterial disease is a common condition in older adults involving poor arterial circulation in the legs leading to leg pain and debility.
- Trial name
- GPAD-2 (NCT01041417)
- Testing
- Granulocyte-Macrophage Stimulating Factor (GM-CSF)
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Emory University
Multiple Myeloma, Non-hodgkin's Lymphoma
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.
- Conditions
- Multiple Myeloma, Non-hodgkin's Lymphoma, Hodgkin's Disease
- Trial name
- NCT01458288
- Testing
- TG-0054
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- GPCR Therapeutics, Inc.
Hodgkin's Disease
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
Participants with Hodgkin's Disease (HD) who have been treated with cyto-reductive chemotherapy, who are to undergo autologous stem cell transplantation, and who meet the inclusion/exclusion criteria are eligible to enter this…
- Trial name
- NCT00396201
- Testing
- G-CSF Plus Plerixafor
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Related Donors Donating PBSC to a Family Member, Healthy Donors
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies.
- Conditions
- Related Donors Donating PBSC to a Family Member, Healthy Donors, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT04762875
- Testing
- MGTA-145, Plerixafor
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Ensoma
Multiple Myeloma
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and…
- Trial name
- CarMob (NCT03909412)
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Hackensack Meridian Health
Multiple Myeloma
Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.
The purpose of the study is to compare safety and efficacy of stem cell mobilization using G-CSF (filgrastim) alone vs. intermediate-dose cytosine arabinoside plus G-CSF in multiple myeloma patients.
- Trial name
- NCT01908621
- Testing
- G-CSF (filgrastim), Cytosine arabinoside + G-CSF (filgrastim)
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Multiple Myeloma
Chemotherapy and G-CSF for Mobilization
This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while associated with fewer side effects in…
- Trial name
- MOCCCA (NCT03442673)
- Testing
- Vinorelbine, Gemcitabine, G-CSF
- Where
- Switzerland
- Volunteers
- 137 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Sickle Cell Trait
Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait
This study will examine the effects of granulocyte colony-stimulating factor (G-CSF) on bone marrow stem cells in healthy volunteers with sickle cell trait and determine if cells collected for transplantation from donors with…
- Trial name
- NCT00005782
- Testing
- Granulocyte colony-stimulating factor, Leukapheresis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Testicular Neoplasms
High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II
High-dose chemotherapy (HD-CT) is able to circumvent platinum-resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low. New strategies are needed with new drugs and a sequential approach.
- Trial name
- NCT00231582
- Testing
- epirubicin, high-dose and autologous stem cell transplantation, paclitaxel
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Peripheral Vascular Diseases
Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease
This study is designed to test the use of G-CSF in peripheral vascular disease. The investigators hypothesize that mobilization of angiogenic cells into the blood by granulocyte colony stimulating factor (G-CSF) may stimulate the…
- Trial name
- STEMPAD (NCT00797056)
- Testing
- G-CSF, Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Washington University School of Medicine
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer
The reason for doing this study is to see if cancer will respond to immune therapy after transplantation of blood stem cells (from the bone marrow) using a new kind of treatment regimen that is less toxic than that previously…
- Trial name
- NCT00005851
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Diabetes Mellitus, Type 1
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
Type 1 diabetes is an autoimmune disease characterized by destruction of pancreatic beta-cells, resulting in absolute deficiency of insulin. Presently there is no known cure.
- Trial name
- NCT03182426
- Testing
- Plerixafor, Alemtuzumab, Anakinra
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Alberta
Leukemia
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
RATIONALE: Drugs used in chemotherapy, such as cladribine, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00072007
- Testing
- filgrastim, rituximab, CHOP regimen
- Where
- 11 sites in Switzerland
- Volunteers
- 43 people
- Sponsor
- Swiss Cancer Institute
DS (Durie/Salmon) Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant
This pilot clinical trial studied how well desipramine hydrochloride and filgrastim worked for stem cell mobilization in participants with multiple myeloma (MM) undergoing stem cell transplant.
- Conditions
- DS (Durie/Salmon) Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01899326
- Testing
- Desipramine Hydrochloride, Filgrastim, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Albert Einstein College of Medicine
Lymphoma, Non-Hodgkin, Hodgkin Disease
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
This study will evaluate the safety and efficacy of intravenous AMD3100 added to a standard G-CSF mobilization regimen of patients undergoing autologous stem cell transplantation for lymphoma.
- Trial name
- NCT00733824
- Testing
- AMD3100, G-CSF, Apheresis
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)
A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers
The purpose of this study is to determine whether BL-8040 is safe, tolerable and effective in the mobilization of Hematopoietic Stem Cells (HSC) in healthy volunteers
- Trial name
- NCT02073019
- Testing
- BL-8040
- Where
- Israel
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- BioLineRx, Ltd.
Non-Hodgkin Lymphoma
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
This phase II trial is studying how well giving rituximab; ifosfamide, carboplatin, and etoposide (ICE) combination chemotherapy; and filgrastim (G-CSF) together with plerixafor works in treating patients with non-Hodgkin…
- Trial name
- NCT01097057
- Testing
- Carboplatin, Etoposide, Filgrastim
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center